ClinicalTrials.gg
WithdrawnNCT03754296TRUSTUpdated Jan 9, 2020

Treatment of Acute Ischemic Stroke With CATCHVIEW Stent Retriever in Comparison to SOLITAIRE 2/FR

An observational study in Acute Ischemic Stroke, sponsored by Balt Extrusion. Withdrawn. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-01-09.

Sponsored by Balt Extrusion · Observational

How we know

Why this study was withdrawn
Strategic decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The TRUST study is a non-interventional, prospective, multicenter, international, single arm and non-inferiority study. It is designed to evaluate the efficacy and safety of mechanical thrombectomy of the CATCHVIEW device compared to SOLITAIRE 2/FR based on an objective performance criterion (OPC) defined with available and published clinical evidence gathered through the Solitaire clinical trials in the arterial revascularization of patients with acute ischemic stroke.

02

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

03

In context

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Lead sponsor

Balt Extrusion is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients with acute onset of stroke symptoms leading to significant clinical deficit in the setting of an angiographically proven occlusion of a proximal intracranial artery (intracranial internal carotid, middle cerebral M1 and/or M2 segments, carotid terminus or tandem proximal ICA/MCA-M1) who could have endovascular therapy (defined as the first pass with assigned study device) started within 8h of onset of stroke symptoms will be eligible for the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 and ≤ 80 years old
  • Clinical signs consistent with acute ischemic stroke
  • Pre-stroke modified Rankin Score ≤ 1
  • Patient able to be treated within 8 hours of onset of stroke symptoms and within 2 hours between qualifying imaging from CTA or MRA to groin puncture
  • Initial NIHSS ≥ 6 and \< 30 at the time of inclusion
  • Arterial occlusion in the intracranial internal carotid, M1/M2 segment of the MCA, carotid terminus or tandem proximal ICA/MCA-M1 confirmed by CT or MR angiography that is accessible to the device
  • Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment or the treatment is (e.g., patient presents beyond recommended time from symptom onset), or where patient has received IV thrombolytic therapy without partial or complete recanalization
  • Primary use of the CATCHVIEW stent retriever for the procedure (decision of use is done independently and prior to the participation of the patient in the study)
  • of at least 90 days
  • Ability of the patient or legally authorized representative to provide a signed and dated form before the procedure. Where applicable, in case of medical emergency not allowing the patient to provide consent and unavailability of the legally authorized representative, a physician who does not take part in the study will sign the informed consent before the procedure. In any case, the patient or the legally authorized representative consent shall be requested as soon as possible after the procedure up until the discharge visit.

Exclusion criteria

Exclusion Criteria:

Clinical exclusion criteria

  • Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal
  • Suspicion of aortic dissection
  • Patient with a co-morbid disease or condition that would confound the neurological and functional evaluations or compromise survival or ability to complete follow-up assessments within 90 days
  • Known history of other arterial disease that would prevent the device from reaching the target vessel and/or preclude safe recovery of the device
  • Patient who requires hemodialysis or peritoneal dialysis, or who have to an angiogram for whatever reason
  • Serious sensitivity to radiographic contrast agents
  • Sensitivity to nickel-titanium
  • Patient with stenosis proximal to the thrombus site that may preclude safe recovery of the device
  • Inability to reach the occlusion site
  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with >3.0
  • Current participation in an interventional investigation drug or device treatment study
  • Pregnant women

Imaging exclusion criteria

  • Baseline non-contrast CT or DWI MRI evidence of a moderate/large core defined as extensive early ischemic changes of Alberta Stroke Program Early CT score (ASPECTS) \< 6
  • Imaging evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for mechanical thrombectomy intervention (e.g. inability to navigate to target lesion, moderate/large infarct with poor collateral circulation, etc.)
  • CT or MRI evidence of hemorrhage on presentation
  • CT or MRI evidence of mass effect or intra-cranial tumour (except small meningioma)
  • Imaging evidence of cerebral vasculitis
  • CT or MRI showing an infarction core involving greater than 1/3 of the MCA territory (or in other territories > 100 cc of tissue) on presentation
  • CT or MRI evidence of a basilar artery (BA) occlusion or posterior cerebral artery (PCA) occlusion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • CATCHVIEW stent retriever

    Device: CATCHVIEW

Interventions

  • DeviceCATCHVIEW

    Revascularization device

06

What researchers measure

Primary outcomes

  1. modified Rankin Score (mRS)

    Proportion of patients achieving functional independence (mRS ≤ 2)

    Time frame: 90 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2018; primary completion for Mar 2020, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2018
First posted
Nov 27, 2018
StartEst.
Dec 2018
Primary completionEst.
Mar 2020
CompletionEst.
Mar 2020
Last update
Jan 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03754296
Lead sponsor
Balt Extrusion
Responsible party
Sponsor
First posted
Nov 27, 2018
Start date
Dec 2018 (estimated)
Primary completion
Mar 2020 (estimated)
Completion
Mar 2020 (estimated)
Last update
Jan 9, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion